The Latest Breaking News from Medicare

Centers for Medicare and Medicaid Services (CMS) finalized its decision to restrict coverage for Biogen Inc's (NASDAQ:&

The Biden administration announced Medicare will cover Aduhelm, but will require patients to be enrolled in a clinical trial in order to access the drug.

Medicare says it’s considering a cut in enrollee premiums, after officials stuck with an earlier decision to sharply limit coverage for a pricey new Alzheimer’s drug projected to drive up program costs

The U.S. Medicare program finalized a plan to only pay for Biogen Inc.’s Alzheimer’s therapy when it’s used in approved clinical trials, while offering a road map to cover drugs that do show clinical benefit in the disease.

Medicare will limit coverage of the drug it to patients who enroll in a clinical study, officials announced Thursday.

The 12-bed centre will be built on Dudley Road at Charlestown, and will provide specialist support to people aged 16 and over with severe eating disorders.

Ahead of the Company's fiscal Q4 results on April 14, Deutsche Bank downgraded Rite Aid Corporation (NYSE:RAD) to Sell from Hold with a price target of $1, down from $16. Analyst George Hill believes COVID has "hastened the decline" for the Company, and he sees the potential for a "dramatic negative inflection point"…

WASHINGTON — Advocates and some lawmakers are hoping to add provisions for the uninsured to a Senate bill that would cap insulin copays for some insured patients — and to do so before the chamber votes on the measure, possibly this month.

The namesake of Obamacare took a victory lap at the White House.

As the Senate prepares to vote on an insulin pricing bill as early as this month, advocates and some lawmakers try to expand its reach.

Net prices are unclear, but patient cost-sharing is often based on a drug's list price.